by Maria Zannes | Mar 31, 2023 | Press Releases
Conference Call Scheduled for April 3, 2023, at 9:00 a.m. Eastern Time SAN ANTONIO, Texas (March 31, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and...
by Maria Zannes | Mar 28, 2023 | Press Releases
SAN ANTONIO, Texas (March 28, 2023) – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced the publication of a paper titled “Porphyrin-modified beads for use as compensation controls in flow cytometry” in the peer-reviewed Journal of Visualized...
by Maria Zannes | Mar 24, 2023 | Publications
JoVE Journal, March 24, 2023 Authors William Bauta, Marcia Grayson, Rossella Titone, Jennifer Rebeles, Vivienne I. Rebel Abstract Flow cytometry can rapidly characterize and quantify diverse cell populations based on fluorescence measurements. The cells are first...
by Maria Zannes | Mar 23, 2023 | Press Releases
SAN ANTONIO, Texas (March 24, 2023) – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a...
by Maria Zannes | Mar 6, 2023 | Articles, News
MARCH 6, 2023 The Empowered Patient podcast host Karen Jagoda recently interviewed bioAffinity Technologies President and CEO Maria Zannes about the development of the CyPath® Lung test for the detection of early-stage lung cancer. Hear the podcast at...
